A Human Trial to Assess the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Soy (SOY-LDL)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is being conducted to test the hypothesis that daily consumption of a baked food product containing whole soy for 6 weeks will significantly reduce plasma Low Density Lipoprotein Cholesterol (LDL-C) in individuals with hypercholesterolemia. As such the overall goals of this study are to determine whether daily consumption of muffins made from whole soy flour for 6 weeks can lower plasma LDL-Cholesterol, and if so, establish whether the effect is dose-dependent. To do this, study collaborators will: (1) conduct a detailed chemical and physical characterization of certified defatted whole soy flour that will be incorporated into a muffin; (2) formulate and produce a palatable whole soy flour muffin along with a control muffin containing wheat flour; (3) conduct a parallel controlled trial in which soy muffins will be fed randomly to persons with elevated LDL-cholesterol in a human clinical trial. All participants will be randomized into one of three groups and asked to eat two muffins daily for 6 weeks in the following combination: high dose soy; control group or low dose soy. Before, after, and mid-way during the feeding period, blood samples will be obtained for measurements of lipids, glucose, insulin, inflammation, and soy phytochemicals. The effect of soy consumption on waist circumference, body mass index (BMI) and blood pressure will also be examined.
| Condition | Intervention |
|---|---|
|
Hypercholesterolemia Cardiovascular Disease CRP |
Other: Standardized soy containing muffin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Basic Science |
| Official Title: | A Randomized Controlled Trial to Determine the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Whole Soy: a Dose Response Study |
- Low Density Lipoprotein Cholesterol (LDL-Cholesterol) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- high sensitivity c-reactive protein (hsCRP) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 243 |
| Study Start Date: | March 2012 |
| Estimated Study Completion Date: | October 2013 |
| Estimated Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Control
- Isocaloric control muffins
|
Other: Standardized soy containing muffin
Standardized muffin containing two levels of soy
Other Name: Soy containing muffins
|
|
Experimental: Low Dose Soy
- Isocaloric muffins containing low dose of soy
|
Other: Standardized soy containing muffin
Standardized muffin containing two levels of soy
Other Name: Soy containing muffins
|
|
Experimental: High Dose Soy
- Isocaloric muffins containing high dose soy
|
Other: Standardized soy containing muffin
Standardized muffin containing two levels of soy
Other Name: Soy containing muffins
|
Eligibility| Ages Eligible for Study: | 35 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Males and females (not pregnant or lactating) aged 35-70 year
- Body mass index (BMI) ≤40kg/m² and ≥18.5kg/m²
- Fasting plasma total cholesterol ≥5.0 and ≤8.0 mmol/L
- Fasting plasma LDL cholesterol ≥3.0 and <5.0 mmol/L.
Exclusion Criteria:
- Fasting plasma triglycerides ≥4.0 mmol/L
- Abnormal liver and kidney function
- Unstable body weight(>3kg change in 3 months) or intention to lose or gain weight;
- Diabetes mellitus (fasting plasma glucose ≥7.0 mmol/L or use of insulin or any hypoglycemic or anti-hyperglycemic medication);
- Use of any prescription or non-prescription drug, prebiotics or probiotics, herbal or nutritional supplement known to affect blood lipids, except for stable doses (no change in 3 months) of thyroxine, oral contraceptive agents, hormone replacement therapy, and medications for controlling blood pressure);
- Major surgical or medical events within the past 3 months;
- Presence of a gastrointestinal disorder or medication that alters the digestion and absorption of nutrients; including antibiotic use within the past 6 weeks.
- Consumption of a diet containing ≥15% of energy from saturated fat;
- Any food allergy or aversion or unwillingness to eat wheat, soy or milk;
- Consumption of ≥5 servings per week of soy based food products;
- Consumption of an average of >2 alcoholic beverages per day;
- Regular smokers (smoking ≥1 cigarette per day) of cigarettes or cigars
Contacts and Locations| Contact: Dan Ramdath, PhD | 519-780-8034 | dan.ramdath@agr.gc.ca |
| Canada, Manitoba | |
| Canadian Centre for Agri-food Research in Health and Medicine | Not yet recruiting |
| Winnipeg, Manitoba, Canada, R2H 2A6 | |
| Contact: Heather Blewett, PhD 204-237-2954 hblewett@sbrc.ca | |
| Principal Investigator: Heather Blewett, PhD | |
| Canada, Ontario | |
| Human Nutraceutical Research Unit. University of Guelph | Not yet recruiting |
| Guelph, Ontario, Canada, N1G 2W1 | |
| Contact: Emily Padhi, BSc, MSc 519-824-4120 ext 53749 epadhi@gmail.com | |
| Contact: Alison Duncan, PhD, RD 519-824-4120 ext 53416 amduncan@uoguelph.ca | |
| Principal Investigator: Alison Duncan, PhD, RD | |
| Glycemic Index Laboratories, Inc | Not yet recruiting |
| Toronto, Ontario, Canada, M5C 2N8 | |
| Contact: Janice Campbell, MSc, CCRP 416-861-0506 ext 201 jcampbell@gilabs.com | |
| Contact: Thomas Wolever, MD, PhD 416-978-5557 thomas.wolever@utoronto.ca | |
| Principal Investigator: Thomas Wolever, MD, PhD | |
| Principal Investigator: | Alison Duncan, PhD, RD | University of Guelph |
| Principal Investigator: | Thomas Wolever, MD, PhD | Glycemic Index Laboratories, Inc |
| Principal Investigator: | Heather Blewett, PhD | Canadian Centre for Agri-food Research in Health and Medicine |
More Information
Publications:
| Responsible Party: | Dan Ramdath, Principal Investigator, Guelph Food Research Centre |
| ClinicalTrials.gov Identifier: | NCT01547585 History of Changes |
| Other Study ID Numbers: | SOY-CVD-2012, RBPI#1746 |
| Study First Received: | March 5, 2012 |
| Last Updated: | March 7, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Guelph Food Research Centre:
|
Cholesterol Cardiovascular disease Soy Dose-response |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Hypercholesterolemia Hyperlipidemias |
Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on June 17, 2013